Comparative Bone Histomorphometry Effects of Combined Denosumab and Teriparatide versus Monotherapy in Postmenopausal Women with Osteoporosis: A Randomized Controlled Trial
{{output}}
Combined treatment with parathyroid hormone (PTH) receptor stimulation (teriparatide 20-μg) and RANKL inhibition (denosumab 60-mg) increases spine and hip bone mineral density (BMD) and improves estimates of bone strength to a greater extent than either monot... ...
